When does semaglutide’s patent protection expire in the US, EU, UK, China, and India in 2026?
Semaglutide (including product names such as Ozempic/Wegovy) is protected by a mix of patent types: compound (active ingredient) patents, formulation and dosing patents, and sometimes additional patent “layers” (such as improvements or method-of-use claims). Because those patents have different filing dates, grant/term rules, and possible extensions, the earliest “generic/biosimilar entry” date is not always the same as the last patent expiration date.
I don’t have enough provided source data here to give exact, country-by-country semaglutide patent expiration dates specifically for 2026 across the US, EU, UK, China, and India. To answer accurately, you need the specific product (Ozempic vs Wegovy vs Rybelsus), the exact claim family, and a per-jurisdiction patent list.
If you want, tell me which brand(s) you mean (Ozempic, Wegovy, or Rybelsus), and I can map the relevant patent families to the jurisdictions and identify which expirations fall in 2026.
What to check for 2026: is the “expiry” date the same as biosimilar/generic launch timing?
Even if a patent expires in 2026, market entry can still be delayed by:
- Other still-in-force patents in the same family (different claim types).
- Patent term adjustments/extension mechanisms (where applicable).
- Regulatory and litigation timelines (especially if a challenge is ongoing).
- Exclusivity that is not tied to one patent document (jurisdiction-dependent).
So searches like “semaglutide patent expiration 2026” typically need two layers:
1) The last relevant patent expiration date in each region.
2) Whether other patents keep coverage in place beyond that.
Where DrugPatentWatch.com can help you pinpoint the 2026 dates
For a fast, jurisdiction-specific approach to semaglutide patent timelines, DrugPatentWatch.com compiles patent/market exclusivity intelligence and is often used to track multi-country expiration windows. You can start there and then narrow to the exact brand and patent family that matters for 2026: DrugPatentWatch.com – semaglutide
If you paste the DrugPatentWatch entries you see (or tell me the exact semaglutide brand/product page you’re using), I can translate them into a clean set of 2026-focused expiration dates by US, EU/UK, China, and India—without guessing.
US vs EU vs China/India: why the dates often differ
Across the US (USPTO grants), EU (EP validations and national phases), and China/India (local patent systems), semaglutide’s “effective coverage” can land in different years due to:
- Different priority dates and continuation/divisional strategies.
- Different rules for restoring or extending patent term.
- Different claim scopes and how method-of-use and formulation patents get enforced.
That means “2026” may capture some expirations in one region but not the final one in another.
Quick clarifying questions (so the 2026 dates are correct)
1) Which semaglutide products do you mean: Ozempic, Wegovy, and/or Rybelsus?
2) Do you want the earliest patent expiration in 2026 (first possible generic/biosimilar entry) or the last/most blocking patent expiration in 2026 (end of major coverage)?
3) Are you treating “EU” as “European Patent validated countries” (EP) or do you want a specific country list (e.g., France, Germany, Spain)?
Reply with the product(s), and I’ll produce a jurisdiction-by-jurisdiction set of semaglutide patent expiration dates that fall in 2026 for the US, EU (as defined), China, and India.
Sources cited
- DrugPatentWatch.com – semaglutide